Canon Kabushiki Kaisha

Takeda Pharmaceutical Company Limited

Tobira Therapeutics, Inc.

Takeda Chemical Industries, Inc.

Canon Finetech Inc.

Solent Therapeutics, LLC

Masaki Seto

Kazuaki Takami

Mitsuru Shiraishi

Masanori Baba

Naoyuki Kanzaki

Haruhi Ando

Masataka Murakami

Yasutomi Asano

Minoru Nakamura

Hideo Suzuki

Tsuneo Oda

Makoto Kamata

Norihito Tokunaga

Toshihiro Imaeda

Yuya Oguro

Masaki Daini

Hironobu Maezaki

Ayumu Sato

Satoshi Mikami

Taku Kamei

Ikuo Fujimori

Shinji Nakamura

Satoshi Yamamoto

Masami Yamada

Masato Yoshida

Shigeo Murayama

Shigemitsu Matsumoto

Takeshi Yamamoto

Takahito Ueno

Takashi Yano

Masato Yoshikawa

Osamu Nishimura

Hiroshi Banno

Tomohiro Okawa

Masaki Ogino

Mitsuhiro Ito

Shinji Morimoto

Satoshi Sasaki

Toshiaki Takeuchi

Takashi Kuwata

Takahiro Sugimoto

Motoyasu Muramatsu

Yuichi Makino

Takateru Ohkubo

Takahiko Taniguchi

Shinobu Sasaki

Yuji Iizawa

Katsuji Aikawa

Zenyu Shiokawa

Takeshi Wakabayashi

Yasufumi Wada

Taisuke Tawaraishi

Tomohiro Ohashi

Steve Swann

Jinichi Yonemori

Akito Shibuya

Michiyo Mochizuki

Morihisa Saitoh

Yusuke Tominari

Tomohiro Seki

Kosuke Hidaka

Yoshihisa Nakada

Yayoi Nakayama

Yasuo Nakagawa

Yusuke Sasaki

Kouichi Iwanaga

Jumpei Aida

Kenichiro Shimokawa

Yuta Tanaka

Paul D Greenspan

Brian Scott Freeze

Takatoshi Yogo

Tomoyasu Ishikawa

Shumpei Murata

Hiroyuki Nagamiya

Bunro Noguchi

Yasuyoshi Arikawa

Keiko Kakegawa

Minoru Sasaki

Tamotsu Kaneko

Mitsunori Kono

Kazuyoshi Aso

Shuji Kitamura

Zenichi Ikeda

Masanori Okaniwa

Makoto Fushimi

Fumiaki Kikuchi

Yoshio Aramaki

Shogo Marui

Tomokazu Kusumoto

Tony Gibson

Hiroshi Imoto

Yuji Ishichi

Naoki Miyamoto

Alison L Chambers

Takuya Terae

Hyun Bin Kang

Kentaro Mori

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

A sheet feeding apparatus includes a stacking portion, a feed member provided above the stacking portion and configured to feed an uppermost sheet among the sheets stacked on the stacking portion, and a trailing-end regulating member movable in the sheet feeding direction and configured to regulate a position of a trailing end of the sheets stacked on the stacking portion in the sheet feeding direction. The trailing-end regulating member includes a support portion configured to support a lower surface of the sheets stacked on the stacking portion. The support portion has a projecting shape in which a center portion of the support portion in a sheet width direction projects upward as compared with end portions of the support portion in the sheet width direction.

Sheet feeding apparatus and image forming apparatus

Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R, R, R, Rand Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Condensed-cyclic compound

Heterocyclic compounds useful as modulators of acetylcholine receptors

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein Ris a hydrogen atom, a halogen atom, an optionally substituted Calkyl group, or an optionally substituted Calkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound and use thereof

Antibody-drug conjugates comprising a cyclic dinucleotide

An image forming apparatus includes a frame having a first metal plate and a second metal plate where the first metal plate has a recess portion. The frame supports an image forming member that forms an image on a sheet. The first metal plate and the second metal plate are positioned to each other and an adhesive is in a space formed between the recess portion and the second metal plate. The space is such that it receives the adhesive by injection.

Image forming apparatus having plates fixed to each other by a fastener and with adhesive

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof. 

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Image forming apparatus having a frame formed by adhering with adhesive

Cyclic dinucleotide

Growing community of inventors

Gotemba, Japan

Masaki Seto